CYP19A1 and colorectal carcinoma: Collectively, our study provides novel insights into the molecular mechanisms underlying chemoresistance in CRC and identifies the CYP19A1/estrogen/complex I axis as a promising therapeutic target for overcoming chemoresistance and improving patient outcomes.